0001636282-26-000099.txt : 20260805 0001636282-26-000099.hdr.sgml : 20260805 20260805213109 ACCESSION NUMBER: 0001636282-26-000099 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260803 FILED AS OF DATE: 20260805 DATE AS OF CHANGE: 20260805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Turtle Cameron CENTRAL INDEX KEY: 0001758363 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 261245587 MAIL ADDRESS: STREET 1: C/O SPYRE THERAPEUTICS, INC. STREET 2: 221 CRESCENT STREET, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1785979866.xml FORM 4 X0609 4 2026-08-03 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001758363 Turtle Cameron false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 1 1 0 0 Chief Executive Officer 1 Common Stock 2026-08-03 4 S 0 800 93.97 D 581740 D Common Stock 2026-08-03 4 S 0 7157 95.10 D 574583 D Common Stock 2026-08-03 4 S 0 5635 95.93 D 568948 D Common Stock 2026-08-03 4 S 0 1392 96.82 D 567556 D Common Stock 2026-08-03 4 S 0 16 97.46 D 567540 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-08-05